Drug Profile
Aminolevulinic acid - Biofrontera
Alternative Names: 5-Aminolevulinic acid - Biofrontera; Ameluz; Aminolevulinic acid hydrochloride - Biofrontera; BF-200 ALALatest Information Update: 16 May 2023
Price :
$50
*
At a glance
- Originator ASAT AG
- Developer Biofrontera AG; Louis Widmer
- Class Amino acids; Antianaemics; Antineoplastics; Diagnostic agents; Imaging agents; Keto acids; Levulinic acids; Nootropics; Skin disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Actinic keratosis; Basal cell cancer
- Phase II Acne vulgaris
- No development reported Condylomata acuminata
Most Recent Events
- 20 Apr 2023 Biofrontera Bioscience completes a phase I trial for Actinic keratosis (Topical) (NCT05060237)
- 23 Dec 2022 Biofrontera Bioscience plans a phase III trial in Actinic keratosis in USA (Topical) in December 2022 (NCT05662202)
- 12 Dec 2022 Biofrontera Bioscience initiates a phase III trial for Actinic keratosis in USA (Topical, Gel) (NCT05662202)